Sulfonylurea

Hypoglycemia was relatively uncommon in the ORIGIN (Outcome Reduction with an Initial Glargine Intervention) trial… ORIGIN trial investigators have published results of their look at treatment with insulin glargine compared with standard care early in the course of dysglycemia, and its effects on hypoglycemia. A total of 12,537 people with …

Can metformin reduce the risk of cancer for those with type 2 diabetes?… In previous studies, metformin has been shown to decrease the risk of cancer in type 2 diabetes. A recent meta-analysis showed a 34% reduction in the incidence of any cancer and a 33% reduction in cancer mortality; …

In this week’s Homerun Slides, we review the positives and negatives of sulfonylureas, comparing them with some of the newer medications available including incretins… To download these slides in PowerPoint (.ppt) format, use this link: Diabetes Mellitus 101 for Cardiologists, Part 13 Other sets in this series: Diabetes Mellitus 101 for Cardiologists, Part …

About 11,000 patients using both insulin and sulfonylurea were evaluated… Ulrik M. Mogensen, MD, of the department of cardiology at University Hospital Rigshospitalet in Denmark, and colleagues evaluated patients receiving sulfonylurea with insulin and 16,910 patients receiving metformin with insulin to determine the differences in outcomes of treatment combinations. Outcome …

Improved glycemic control can reduce A1c, medical costs and complications… According to a new study, early introduction of insulin could save money, help more patients reach A1c goals and decrease diabetes-related complications and mortality. Currently, insulin therapy for persons with type 2 diabetes is traditionally added to an anti-hyperglycemic regimen …

Saxagliptin shows improved glycemic control when added to other classes of medications in type 2 diabetes patients… Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by extending the half-life of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The medication can be used as monotherapy or in combination with …

Use over 10-year period also leads to cardiac events in type 2 patients using metformin monotherapy… Cardiovascular disease is a common comorbid complication in type 2 diabetes patients. 50-80% of type 2 diabetes patient deaths are a result of a cardiovascular disease. Sulfonylureas are one of the most widely prescribed …

Study finds drug combination increases costs and morbidity rates…. In a retrospective cohort study, researchers assessed Texas Medicare claims from 2006 to 2009 for patients 66 years or older who were prescribed glipizide or glyburide and who also filled a prescription for 1 of the 16 antimicrobials most commonly prescribed. …

This week, we’re taking a break from our regularly featured section on avoiding medication mistakes to bring you this exclusive interview series with NuSirt CEO, JC, in which he talks about some of the groundbreaking work his company is doing to increase the effectiveness of metformin. Steve Freed, Publisher, Diabetes …

The once-daily oral tablet is the first in the U.S. to combine the SGLT-2 inhibitor dapagliflozin with the biguanide extended-release (XR) metformin hydrochloride.. The US Food and Drug Administration (FDA) has approved a once-daily combination of dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with …